Hundreds of bad reactions linked to weight loss jabs prompts new study
Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting health officials to launch a new study into side effects.
Some cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like peptide-1 receptor agonists) have been fatal.
Data from the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), shows that since the drugs were licensed there have been hundreds of cases of acute and chronic pancreatitis among people taking GLP-1 medicines.
Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions.
Dr Alison Cave, MHRA
This includes:
These cases are not confirmed as being caused by the medicines, but the person who reported them suspected they may be.
Nonetheless, Yellow Card Biobank project, launched by the MHRA and Genomics England, will see researchers examine whether cases of pancreatitis linked to GLP-1 drugs may be influenced by peoples genetic makeup.
The MHRA is calling for people who are taking GLP-1 medicine who have been admitted to hospital due to acute pancreatitis to submit a report to its Yellow Card scheme.
When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to take part in the study.
Patients will be asked to submit more information and a saliva sample which will be assessed to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genes.
GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss.
Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs.
Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects.
Most side effects linked to the jabs are gastrointestinal including nausea, constipation and diarrhoea.
And the medical regulator recently warned that Mounjaro may make the oral contraceptive pill less effective in some patients.
Dr Alison Cave, MHRA's chief safety officer, said: 'Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone.
'Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions – enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup.
'To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme.
'Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety.'
Professor Matt Brown, chief scientific officer of Genomics England, said: 'GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects.
'We believe there is real potential to minimise these with many adverse reactions having a genetic cause.
'This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
4 hours ago
- Telegraph
Weight-loss jabs linked to pancreas problems after 10 deaths
Weight-loss jabs have been linked to pancreas problems after 10 patients died. Hundreds of people have reported problems with their pancreas linked to taking weight-loss and diabetes jabs including Mounjaro, Wegovy and Ozempic, prompting health officials to launch a new study into side effects. Ten cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like peptide-1 receptor agonists) have been fatal. Since the GLP-1 medicines were licensed, there have been hundreds of cases of acute and chronic pancreatitis, according to data from the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA). These cases are not confirmed as having been caused by the medicines, but the person who reported them suspected they might be. They include 181 reported cases of acute and chronic pancreatitis linked to tirzepatide - the active ingredient for Mounjaro - and five of those people died. Some 116 reported reactions of this kind were linked to liraglutide, one of which was fatal, while there were 113 cases of acute and chronic pancreatitis linked to semaglutide - the active ingredient for Ozempic and Wegovy - where one person died, and 101 reported reactions of this kind were linked to exenatide, from which three people died. Then there were 52 reported reactions linked to dulaglutide and 11 reported reactions linked to lixisenatide, but no fatalities were linked to either drug. Pancreatitis is the inflammation of the pancreas, a gland located behind the stomach that aids in digestion and blood sugar regulation. In severe cases it can lead to organ failure. Nonetheless, the Yellow Card Biobank project, launched by the MHRA and Genomics England, will see researchers examine whether cases of pancreatitis linked to GLP-1 drugs may be influenced by genetic makeup. The MHRA is calling for those who are taking GLP-1 medicine, who have been admitted to hospital due to acute pancreatitis, to submit a report to its Yellow Card scheme. When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to take part in the study. Patients will be asked to submit more information and a saliva sample, which will be assessed to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genes. GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss. Recent estimates suggest that about 1.5 million people in the UK are taking weight-loss jabs. Health officials have suggested they can help turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects. Most side effects linked to the jabs are gastrointestinal including nausea, constipation and diarrhoea. And the medical regulator recently warned that Mounjaro may make the oral contraceptive pill less effective in some patients. Dr Alison Cave, the MHRA's chief safety officer, said: 'Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone.' She added: 'Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions - enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup. 'To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme. 'Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety.' Professor Matt Brown, chief scientific officer of Genomics England, said: ' GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects. 'We believe there is real potential to minimise these with many adverse reactions having a genetic cause. 'This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.'
Glasgow Times
5 hours ago
- Glasgow Times
Mounjaro could be available on prescription by Glasgow health board
Health board bosses are looking into costings around giving Mounjaro to obese patients whose health they believe could benefit from the slimming jab. The move comes after senior officials at NHS England gave GPs permission to issue the drug to 220,000 severely overweight people with associated health problems over the next three years. In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of over 40 who have at least four other health problems linked to obesity such as type 2 diabetes; high blood pressure; heart disease and obstructive sleep apnoea. Mounjaro, also known as tirzepatide, works by regulating the user's appetite by mimicking a naturally produced hormone called glucagon-like peptide-1 (GLP-1). When we eat, GLP-1 is released and signals sent to the brain to reduce the feeling of hunger. Currently patients in Glasgow can only access the injections through a specialist weight service or at a pharmacy, where the jabs cost around £209 per month. Initially developed for the management of type 2 diabetes, the medication has been licensed in the UK for obesity treatment since November 2024, earning acclaim for its effectiveness in helping with rapid and substantial weight loss. Freedom of Information requests show that 5,866 people are currently being seen by specialist weight loss services in Scotland, but doctors say the number of people who would benefit from a weight loss drug is far higher. After the Scottish Medicines Consortium (SMC) granted approval, there was concern that not all health boards had a weight management service model to support the recommendations - and that the potential level of uptake, along with ongoing supply issues, could pose a challenge for budgets. Any patients being prescribed the drugs on the NHS would need to see a specialist before starting the injections. Professor Naveed Sattar, from Glasgow University, is chair of the UK government's Obesity Mission. He says that when such breakthrough drugs comes along - like statins did 30 years ago - they are expensive at first, but then prices start to fall, making them more widely affordable to health chiefs. Prof Sattar believes the trend would mean medics would then be able to "widen the net" of people who could be prescribed Mounjaro on the NHS. We previously told how Angela Brown reversed her type 2 diabetes and lost five and half stone after turning to the jags, which have also become a favourite of celebrities such as Elon Musk and singer Meghan Trainor. Angela Brown (Image: Colin Mearns) READ NEXT: Cumbernauld woman's surgery goal after Mounjaro weight loss The 52-year-old gran from Cumbernauld tipped the scales at 24 stone and knew she had to quickly shed the pounds to get her health back on track. Angela said: 'I overhauled my diet and lost six stone initially, taking me to 18 stone, but I struggled to shift the rest. I tried everything but nothing seemed to work, then after taking medical advice, I started using Mounjaro and the weight just melted away. It helped my metabolism to kick in and I lost another five and a half stone.' A spokesperson for NHSGGC added: 'We are currently exploring prescribing and monitoring pathways for Mounjaro to patients before inclusion in the GGC formulary.'
Sky News
6 hours ago
- Sky News
Why weight loss jabs might not be a wonder drug
👉 Listen to Sky News Daily on your podcast app 👈 Recent years have seen the advent of weight loss drugs, including Ozempic and Wegovy. They work by suppressing users' appetites, leading to weight loss. They've been described as wonder drugs but now, new figures from the Medicines and Healthcare products Regulatory Agency (MHRA) show they may be associated with inflammation of the pancreas, which could lead to death. Niall Paterson speaks to Sky's science correspondent Thomas Moore about these new findings and how cautious they should make us. We also hear from Lorna, a mother who got acute pancreatitis while she was on a weight loss drug - she believes the drugs are not worth the risks.
